Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 8/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6452267 | 1.00 | MMP12 (0.68) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6450858 | 0.88 | HDAC6 (0.57) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6456462 | 0.88 | MMP12 (0.72) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6878595 | 0.87 | MMP12 (0.55) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6878598 | 0.87 | MMP12 (0.55) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6455095 | 0.87 | MMP12 (0.71) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL6881474 | 0.86 | MMP12 (0.70) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6370030 | 0.81 | MMP12 (1.00) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6370033 | 0.81 | MMP12 (1.00) | MMP12HDAC4HDAC6HDAC3HDAC1 | |
| SCHEMBL6879815 | 0.81 | MMP12 (1.00) | MMP12HDAC4HDAC6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885HDAC4 484/4885HDAC6 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.